Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
- ASKA Aims for 70 Billion Yen Sales by FY2025 on Growth of OB-GYN, Thyroid Spaces: New Biz Plan
March 23, 2021
- Takecab OD Tablet Filed in Japan: Takeda/Otsuka
March 23, 2021
- Lenvima/Keytruda Combo Cuts Risk of Death by 38% in Endometrial Cancer
March 22, 2021
- KM Biologics Begins Formulation of AstraZeneca’s COVID-19 Vaccine
March 22, 2021
- Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
March 22, 2021
- Nippon Shinyaku Gets Japan Rights to Menarini’s Blood Cancer Med
March 19, 2021
- Takeda Rolls Out Music App to Encourage Exercise for Parkinson’s Patients
March 18, 2021
- PII Study Now underway for StemRIM’s Redasemtide for Chronic Liver Disease
March 18, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
- Eisai, German Institute Link Arms on Neurodegenerative Disorder Research
March 18, 2021
- Torii Gets Japan Rights to Verrica’s Wart Drug
March 18, 2021
- Shionogi Curbing Supplies of Claritin Dry Syrup after Alesion Recalls
March 18, 2021
- Sawai Reaches Settlement over Doping Substance Contamination Lawsuit
March 18, 2021
- Fujifilm Invests 100 Million Yen in Cell Therapy Startup Cuorips
March 17, 2021
- Eisai’s Anti-Tau Antibody Picked for US Prevention Trial for Inherited Alzheimer’s
March 17, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Morimoto Pharma Looking to Partner with Drug Makers, CMOs to Develop Freeze-Dried COVID Vaccines in Japan
March 17, 2021
- Otsuka Grabs Japan Rights to Perception’s Antidepressant
March 17, 2021
- Nippon Shinyaku Taps Global-Savvy Toru Nakai as New President
March 17, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…